CPI-818
Corvus
['lymphoma']
corvus pharmaceuticals presents data from cpi-818 phase 1/1b at 64th american society of hematology annual meeting! results in patients with t cell lymphoma demonstrated anti-tumor activity, indicating therapeutic potential! $crvs #biotech #ash22 
Investor Relations & PR firm working w/ growth #LifeSciences #Tech #Mining #Consumer companies to connect #WallStreet #Investors — No investment advice / DYODD